CervoMed Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $24.3M
- Price
- $2.62
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.34%
- Volume
- 269.6K
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding9.3M
Computed float8.5M
Float / shares92.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001053691
Websitehttps://www.cervomed.com
AI Summary
AI-generated1/23
standardbullishoperations update
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed reported Q2 financial results with a net loss of $6.6 million and no grant revenue, following the completion of its RewinD-LB trial.
The company closed two equity financings for aggregate gross proceeds of $20.5 million, extending its cash runway into the third quarter of 2027.
New data analyses at AAIC 2026 reinforced neflamapimod's treatment effect in pure DLB, supporting a 50 mg TID dose for a planned Phase 3 trial, while the drug received an Innovation Passport designation in the UK.
Red flags
- Company states strategic partnership is required to advance neflamapimod into Phase 3
- Grant revenue dropped to $0 from $1.8M YoY following trial completion